KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
300142 Walvax Biotechnology
- 13.54
- -0.80-5.58%
Market Closed Dec 13 15:00 CST
21.66BMarket Cap175.84P/E (TTM)
14.27High13.47Low1.11MlotVolume14.26Open14.34Pre Close1.52BTurnover7.14%Turnover Ratio51.68P/E (Static)1.60BShares23.9852wk High2.26P/B21.11BFloat Cap9.7852wk Low17.21Limit Up1.56BShs Float96.68Historical High11.47Limit Down5.58%Amplitude3.57Historical Low0.01Dividend TTM13.70Avg Price555.19KlotAsk0.07%Div YieldTTM100Lot Size443.56KlotBid
Walvax Biotechnology Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -27.57%2.48B | -28.63%1.48B | -36.56%595.88M | 10.78%4.7B | 13.52%3.42B | 19.54%2.08B | 50.98%939.34M | 33.89%4.25B | 52.29%3.02B | 53.17%1.74B |
| Refunds of taxes and levies | ---- | ---- | ---- | -92.26%4.33M | ---- | ---- | ---- | --55.96M | --55.96M | --57.08M |
| Cash received relating to other operating activities | -68.62%99.45M | -55.24%80.9M | -62.38%35.96M | 15.41%376.48M | 13.95%316.91M | -8.79%180.77M | -45.71%95.59M | 11.16%326.21M | 27.99%278.12M | 132.64%198.18M |
| Cash inflows from operating activities | -31.05%2.58B | -30.75%1.57B | -38.95%631.85M | 9.86%5.08B | 11.66%3.74B | 13.30%2.26B | 29.65%1.03B | 33.58%4.63B | 52.44%3.35B | 63.39%1.99B |
| Goods services cash paid | -31.40%1.45B | -24.55%1.05B | -27.11%445.58M | 28.58%2.99B | 30.06%2.11B | 27.24%1.39B | 16.31%611.31M | 20.23%2.32B | 23.93%1.62B | 29.98%1.1B |
| Staff behalf paid | 2.95%387.43M | 4.02%283.28M | 11.88%184.5M | 30.59%487.07M | 40.09%376.33M | 46.49%272.32M | 37.49%164.91M | 23.18%372.99M | 24.82%268.63M | 24.17%185.9M |
| All taxes paid | -47.84%116.52M | -43.84%86.96M | -13.56%46.68M | -26.56%268.45M | -23.48%223.4M | 32.37%154.84M | 20.49%54M | 49.46%365.52M | 48.00%291.94M | -16.96%116.97M |
| Cash paid relating to other operating activities | -59.45%69.57M | -1.76%52.74M | 1,922.32%30.68M | -42.86%209.09M | -42.24%171.58M | -72.38%53.69M | -98.45%1.52M | 30.40%365.9M | 40.05%297.08M | 97.18%194.37M |
| Cash outflows from operating activities | -29.86%2.02B | -21.34%1.47B | -14.94%707.44M | 15.29%3.95B | 16.17%2.88B | 17.71%1.87B | 5.52%831.73M | 24.18%3.43B | 28.26%2.48B | 29.28%1.59B |
| Net cash flows from operating activities | -35.02%559.4M | -76.51%90.6M | -137.20%-75.59M | -5.64%1.13B | -1.19%860.94M | -4.13%385.67M | 1,922.82%203.2M | 70.36%1.2B | 228.66%871.26M | 3,779.99%402.26M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | ---- | ---- | ---- | ---- | --140M | --140M | ---- | ---- | ---- | ---- |
| Cash received from returns on investments | -28.92%4.82M | ---- | ---- | 8.33%6.78M | 8.33%6.78M | --6.78M | ---- | 9.09%6.26M | 9.09%6.26M | ---- |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -86.79%52.41K | -79.78%47.13K | ---- | 115.35%737.3K | 63.14%396.77K | 259.60%233.11K | --198.35K | -90.83%342.37K | -92.56%243.21K | -98.00%64.83K |
| Net cash received from disposal of subsidiaries and other business units | ---- | ---- | ---- | -6.28%140M | ---- | ---- | ---- | 97.39%149.39M | ---- | ---- |
| Cash inflows from investing activities | -96.69%4.87M | -99.97%47.13K | ---- | -5.43%147.52M | 2,162.33%147.18M | 226,688.68%147.02M | --198.35K | -17.38%155.99M | -95.09%6.51M | -99.95%64.83K |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -38.27%445.3M | -34.31%304.98M | -38.46%153.55M | -13.35%945.52M | -13.70%721.41M | -12.17%464.26M | 52.51%249.53M | -1.12%1.09B | 6.13%835.91M | 22.91%528.58M |
| Cash paid to acquire investments | --32M | --32M | --8.8M | --10M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash paid relating to other investing activities | --700M | --700M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | 63.19%1.18B | 123.36%1.04B | -34.94%162.35M | -12.43%955.52M | -13.70%721.41M | -12.17%464.26M | 52.51%249.53M | -6.41%1.09B | -0.92%835.91M | 8.75%528.58M |
| Net cash flows from investing activities | -104.17%-1.17B | -226.86%-1.04B | 34.89%-162.35M | 13.60%-807.99M | 30.77%-574.23M | 39.97%-317.24M | -52.39%-249.33M | 4.29%-935.19M | -16.65%-829.4M | -49.53%-528.51M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | ---- | ---- | -97.17%18.9M | -96.94%18.9M | -96.45%18.9M | -96.39%18.87M | -45.36%667.11M | 15.10%618.38M | -6.20%532.05M |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --270M | --270M | --270M |
| Cash from borrowing | -83.56%38.22M | -72.46%38.22M | ---- | 26.79%499.31M | -30.81%232.47M | -42.37%138.75M | --45.47M | -3.95%393.82M | 7.69%335.98M | 4.67%240.74M |
| Cash received relating to other financing activities | -99.82%182.58K | -99.82%182.58K | -99.66%183.94K | -76.44%113.79M | -67.18%102.1M | 452.42%100.43M | 50.73%54.11M | -2.54%483.1M | -32.75%311.07M | --18.18M |
| Cash inflows from financing activities | -89.14%38.4M | -85.12%38.4M | -99.84%183.94K | -59.07%632.01M | -72.07%353.47M | -67.37%258.07M | -78.82%118.45M | -27.40%1.54B | -3.53%1.27B | -0.79%790.97M |
| Borrowing repayment | 248.12%104.61M | 5,072.39%84.31M | --147.35K | -87.18%50M | -88.95%30.05M | -98.98%1.63M | ---- | 178.57%390M | 84.08%272M | 100.00%160M |
| Dividend interest payment | 49.37%27.33M | 23.09%21.04M | 388.33%2.47M | -60.12%19.98M | -62.95%18.29M | -64.27%17.09M | -76.31%506.79K | -39.85%50.11M | -39.53%49.38M | -40.49%47.83M |
| Cash payments relating to other financing activities | -92.15%24.43M | -92.86%17.11M | -89.47%11.79M | -67.76%325.38M | -64.08%311.38M | 52.29%239.54M | 113.28%111.9M | 504.43%1.01B | 741.02%866.81M | 1,133.05%157.3M |
| Cash outflows from financing activities | -56.53%156.37M | -52.59%122.45M | -87.18%14.41M | -72.72%395.36M | -69.72%359.72M | -29.27%258.26M | 50.67%112.41M | 271.34%1.45B | 257.36%1.19B | 110.91%365.12M |
| Net cash flows from financing activities | -1,785.58%-117.97M | -45,630.19%-84.05M | -335.46%-14.22M | 149.58%236.64M | -108.10%-6.26M | -100.04%-183.8K | -98.75%6.04M | -94.54%94.82M | -92.11%77.25M | -31.77%425.85M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -309.85%-5.46M | -20.30%836.95K | 128.92%93.31K | -44.09%2.27M | -56.47%2.6M | 4,136.08%1.05M | -672.83%-322.69K | 3,359.61%4.07M | 27,703.95%5.98M | 57.36%-26.02K |
| Net increase in cash and cash equivalents | -360.18%-736.45M | -1,585.90%-1.03B | -523.76%-252.07M | 54.63%564.69M | 126.28%283.05M | -76.87%69.29M | -112.21%-40.41M | -75.06%365.19M | -76.55%125.09M | 15.36%299.57M |
| Add:Begin period cash and cash equivalents | 14.90%4.35B | 14.90%4.35B | 14.88%4.35B | 10.66%3.79B | 10.66%3.79B | 10.66%3.79B | 10.68%3.79B | 74.70%3.42B | 74.70%3.42B | 74.70%3.42B |
| End period cash equivalent | -11.17%3.62B | -13.84%3.33B | 9.39%4.1B | 14.90%4.35B | 14.74%4.07B | 3.62%3.86B | -0.15%3.75B | 10.66%3.79B | 42.35%3.55B | 67.76%3.72B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
